天境生物科技（上海）有限公司 IMab
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022 2022-03-18 20:00
I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act 2022-03-15 20:00
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022-03-09 21:00
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer 2022-03-03 21:00
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs 2022-01-28 21:00
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors 2022-01-18 21:00
I-Mab Announces Execution of Senior Management Team Share Purchase Plan 2022-01-14 21:00
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors 2022-01-12 21:00
I-Mab Announces Senior Management Team Share Purchase Plan 2022-01-06 21:00
I-Mab Announces Upcoming Participation at January Conferences 2021-12-31 21:00
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors 2021-12-27 21:00
I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization 2021-12-20 21:00
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China 2021-12-15 21:00
I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma 2021-12-09 21:00
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease 2021-12-08 21:00
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited 2021-12-07 21:00
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors 2021-12-03 21:00
I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa 2021-11-10 17:30
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC 2021-11-09 21:05
I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE 2021-11-08 21:00
1 2 3 4 5 8